Edaravone for new anti-AQP4 optic neuritis
Part of Brain & nervous system, Eyes & vision clinical trials.
This trial tests edaravone, a medicine intended to reduce damage from optic neuritis, in adults whose condition is confirmed by a positive blood test for anti-AQP4 antibodies. It may help people who are in the first month after their first episode to preserve or improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and able to join as a Chinese patient
- Your optic neuritis is confirmed by a positive anti-AQP4 antibody test
- This is your first episode of optic neuritis (in either eye)
- Your first symptoms started 30 days or less before the first edaravone dose
- You do not have severe nearsightedness (myopia worse than 6 diopters)
- Eye media clarity is good enough for doctors to measure retinal layers and your vision accurately
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called efgartigimod for people having their first episode of optic neuritis (inflammation of the optic nerve). The goal is to see if it can help protect your vision better than standard treatment alone.
This trial tests a medicine called edaravone dexborneol to see if it helps people recover from a recent ischemic stroke (a stroke caused by a blocked blood vessel). The medicine is given within 48 hours of the stroke, and the study will compare how well it works and if it is safe.
This study tests a new treatment called CC-97540 (a type of CAR T-cell therapy) for people with neuromyelitis optica spectrum disorder (NMOSD), which is an autoimmune disease that affects the eyes and spinal cord. The goal is to see if this treatment is safe and tolerable.
This trial is testing whether a medicine called edaravone can help people who recently had a mild or moderate stroke caused by a blocked blood vessel in the brain. It aims to see if the drug improves recovery when given within the first two days after stroke symptoms start.
This trial tests a new drug called ANXV (Annexin A5) to see if it is safe and can help people with diabetic retinopathy or a recent retinal vein occlusion. The goal is to reduce eye damage and improve vision.
This trial tests a new treatment called modified zipper therapy for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4-IgG) in their blood. It aims to stop a recent attack and improve recovery.
Hear when a new Optic Neuritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.